Neogen Chemicals Limited Intrinsic Value
NEOGEN · Chemicals · Current price ₹2,494.2
Is Neogen Chemicals Limited undervalued?
We estimate the fair value of Neogen Chemicals Limited at ₹838 per share, against a market price of ₹2,373. That puts the share price about -64.7% above our estimate, at medium confidence. This is our view of what the business is worth, not a target price or a forecast of where the share price will go.
How this fair value is calculated
This estimate comes from 1 method: Fair multiple (P/E) (₹838). Each is weighted by how well its inputs held up for this company. The full working, including the assumptions and what data was missing, is set out below.
The range around this estimate
Our estimate for Neogen Chemicals Limited spans ₹754 to ₹922. A margin of safety means buying meaningfully below the estimate: the wider the range, the more room the assumptions leave for error.
Margin of safety
Value investors look for a margin of safety: a discount to estimated value that absorbs being wrong. At ₹2,373 against an estimated value of ₹838, Neogen Chemicals Limited trades at -64.7%, i.e. a premium to our estimate. How much margin to demand depends on how much you trust the inputs, which is what the confidence band below is for.
How we got this fair value
Every number below is part of the same estimate for Neogen Chemicals Limited. Nothing here is a target price or a forecast of where the share price will go.
Workable, with real gaps. Weigh it alongside your own view rather than on its own.
Estimate range ₹754 – ₹922
Why this method for this business
Normalized earnings and EV/EBITDA are appropriate for a specialty chemicals company with cyclical characteristics, while relative PE captures market sentiment and peer dynamics.
The models behind the number
Each method is weighted by how well its inputs held up for this company.
value is not a positive, finite number
required inputs missing
- Fair multiple (P/E) was excluded due to the lack of a clear sector-median anchor and the presence of a strong own-history P/E which may distort the fair value
What was missing
- Lack of forward EPS estimates
- Limited analyst coverage
- Insufficient historical P/E data for sector comparison
What drives it
16 inputs, grouped by how strong each claim is
- Sector-median P/E
- 38.17×
- Peers used
- 25
- EPS (TTM)
- 13.25 ₹/share
- Own-history median P/E
- 88.39×
peer-median
peer-median
computed
reconstructed (one feature, dampened — not a cap)
- Anchor correction
- peer anchor 38.2x diverges 2.3x from 7yr own-history 88.4x (no size-comparable peer) — anchor blended 0.6 toward own-history → 68.3x
- Term: quality
- -5.1%
- Term: growth
- +6.8%
- Term: capital_allocation
- -15.0%
- Term: financial_strength
- -2.4%
- Term: history
- +8.8%
- Term: sector_rerating
- +0.0%
- Term: rate_regime
- +1.2%
- Term: risk
- +0.0%
peer-anchor mismatch — deep own-history used instead
quality 45/100 (weak/erratic returns) → discount
durable ~10% CAGR (ROCE 17% > hurdle) → premium
capital allocation: falling ROCE / weak cash generation → discount
financial strength: elevated leverage (D/E 0.9) → mild discount
history: market paid +29% vs sector, dampened ×0.3 (one feature, not the anchor)
sector re-rating: no sector-norm history → not used
rates: risk-free 6.9% below ~7.1% normal → higher multiple
risk: no analyst-dispersion signal available → neutral (lowers confidence, not PE)
- Premium vs sector
- -7.4%
- Fair-multiple confidence
- 72%
- Fair P/E
- 63.27×
fundamentals + macro (not capped at own history)
data completeness + term agreement
sector median × ∏(1+term) — Dynamic Fair Multiple
Who computed this
A language model (qwen3:8b) selects the valuation method and the judgement inputs for Neogen Chemicals Limited: which models suit the business, the moat, the growth and margin assumptions. It does not produce the number. The fair value itself is computed in Python by a deterministic engine (version 2026.08.1) from those inputs, so the same inputs always give the same result and every figure above can be traced to a source.
Estimated 14 Sept 2026. Re-run as new financials and news arrive.
How we value stocks
We estimate what a business is worth from its own economics: cash flows, returns on capital, and a multiple justified by its quality, rather than from where the share price has been. A fair value estimate is a view, not a verdict, and it is only as good as the inputs listed above.
Read the full fair-value methodologyMore on Neogen Chemicals Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.